Novartis has been given the OK to market its aromatase inhibitor, Femara (letrozole), as a treatment for use after surgery in postmenopausal women with hormone-sensitive early breast cancer. Approval of the new indication was based on results from the Breast International Group (BIG 1-98) study, which showed an additional 21% reduction in risk for cancer recurrence over tamoxifen therapy and a 27% reduction in the risk of cancer metastases to distant parts of the body. The drug was given a six-month priority review.
Pharmaceutical Compounding, Storage of Faricimab Preserves Stability, Binding Properties
November 28th 2023Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.